CREATE Medicines, Inc. (formerly Myeloid Therapeutics), a clinical-stage biotech pioneering in vivo multi-immune programming, today announced that clinical results from its Phase 1 MYE Symphony trial ...
Biogen Inc. ? will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of Nephrology's (ASN) annual meeting, taking place November 5-9 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback